Skip to main content

Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine

User login

Username

Password

Reset your password

Type	Lead	score